


**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**


1. (cancelled)

2. (currently amended) A compound ~~in accordance with claim 1~~ of formula (Ia)



~~(where~~ wherein:

~~X<sub>1</sub> and X<sub>2</sub> represent independently~~ represents a hydrogen atom or, and X<sub>2</sub> represents a group of formula (II)



X<sub>1</sub> represents a group of formula (II), and X<sub>2</sub> represents a hydrogen atom;

in which:


R<sub>1</sub> represents a ~~linear or branched halogenoalkyl~~ nonafluoro-n-butyl group;

~~m is an integer of 2-14~~ 8; and

~~n is an integer of 2-7~~ 3; or


~~provided that X<sub>1</sub> and X<sub>2</sub> are not both a hydrogen atom), stereoisomers of the compound, or hydrates, salts or esters thereof.~~

**3. (currently amended)** A compound ~~in accordance with~~  
~~claim 1~~ of formula (Ib)



~~(where~~wherein:

~~X<sub>1</sub> and X<sub>2</sub> represent independently~~represents a  
hydrogen atom, and X<sub>2</sub> represents ~~or~~ a group of formula (II)



X<sub>1</sub> represents a group of formula (II), and X<sub>2</sub>  
represents a hydrogen atom;

in which:

R<sub>1</sub> represents ~~a linear or branched halogenoalkyl~~  
~~group having 1-7 carbon atoms~~ nonafluoro-n-butyl group;

R<sub>b</sub> represents ~~a linear or branched alkynyl~~ an ethynyl  
~~group having 2-5 carbon atoms;~~

~~m is an integer of 2-14~~ 8; and

~~n is an integer of 2-7~~ 3; or

~~provided that X<sub>1</sub> and X<sub>2</sub> are not both a hydrogen atom),~~

~~stereoisomers of the compound, or hydrates, salts or~~  
esters thereof.

**4-5. (cancelled)**


**6. (currently amended)** A pharmaceutical composition

comprising the compound, stereoisomers of the compound, ~~or~~  
~~hydrates,~~ salts or esters thereof according to claim ~~1-2~~ 2 as an  
active ingredient, together with a pharmaceutically acceptable  
excipient.

**7. (previously presented)** The pharmaceutical  
composition according to claim 6 formulated for use to prevent  
or treat osteoporosis.


**8. (previously presented)** The pharmaceutical  
composition according to claim 6 formulated for use to prevent  
or treat breast cancer.

**9. (currently amended)** A process for producing a  
compound of formula (Ia)



~~(where~~ wherein:

~~X<sub>1</sub> and X<sub>2</sub> represent independently~~ X<sub>1</sub> and X<sub>2</sub> represent independently a  
hydrogen atom, and X<sub>2</sub> represents ~~or~~ a group of formula (II)



X<sub>1</sub> represents a group of formula (II), and X<sub>2</sub>  
represents a hydrogen atom;

in which:

R<sub>1</sub> represents a ~~linear or branched halogeneoalkyl~~

~~group having 1-7 carbon atoms~~ nonafluoro-n-butyl group;


~~m is an integer of 2-14~~ 8;

~~n is an integer of 2-7~~ 3; or


~~provided that X<sub>1</sub> and X<sub>2</sub> are not both a hydrogen atom),~~

~~stereoisomers of the compound, or hydrates,~~ salts or  
esters thereof, said process including the step of:

oxidizing a compound of formula (III)



~~(where X<sub>1</sub> and X<sub>2</sub> represent independently a hydrogen atom or a  
group of formula (II))~~



~~R<sub>1</sub> represents a linear or branched halogenoalkyl group  
having 1-7 carbon atoms;~~

~~m is an integer of 2-14;~~


~~n is an integer of 2-7;~~

~~provided that X<sub>1</sub> and X<sub>2</sub> are not both a hydrogen atom),~~ wherein  
X<sub>1</sub> and X<sub>2</sub> are defined as above, or stereoisomers of the  
compound, ~~or hydrates,~~ salts or esters thereof.

**10. (original)** The process according to claim 9, in  
which the oxidation reaction is performed by Oppenauer


oxidation.

**11. (currently amended)** A process for producing a compound of formula (Ib)



~~(where~~wherein:

~~X<sub>1</sub> and X<sub>2</sub> represent independently~~represents a  
~~hydrogen atom, or~~and X<sub>2</sub> represents a group of formula (II)



X<sub>1</sub> represents a group of formula (II), and X<sub>2</sub>  
represents a hydrogen atom;

in which:

~~R<sub>1</sub> represents a linear or branched halogenoalkyl~~  
~~group having 1-7 carbon atoms~~nonafluoro-n-butyl group;

~~R<sub>b</sub> represents a linear or branched alkynyl~~ethynyl  
group having 2-5 carbon atoms;


~~m is an integer of 2-14~~8; and

~~n is an integer of 2-7~~3; or

~~provided that X<sub>1</sub> and X<sub>2</sub> are not both a hydrogen atom),~~


stereoisomers of the compound, ~~or hydrates,~~ salts or  
esters thereof, said process including the step of:

alkynylating a compound of formula (Ia)



~~(where~~ wherein:

$X_1$  and  $X_2$  are defined as above; or represent  
~~independently a hydrogen atom or a group of formula (II)~~



~~$R_1$  represents a linear or branched halogenoalkyl group having  
 1-7 carbon atoms;~~

~~$m$  is an integer of 2-14;~~

~~$n$  is an integer of 2-7;~~

~~provided that  $X_1$  and  $X_2$  are not both a hydrogen atom);~~

stereoisomers of the compound, ~~or hydrates,~~ salts or  
 esters thereof.

**12. (new)** A pharmaceutical composition comprising the  
 compound, stereoisomers of the compound, salts or esters  
 thereof according to claim 3 as an active ingredient.

**13. (new)** The pharmaceutical composition according to  
 claim 12 which is used to prevent or treat osteoporosis.

**14. (new)** The pharmaceutical composition according to  
 claim 12 which is used to prevent or treat breast cancer.